RE: This Coming Week - Part 4 Cont...16 Aug 2019 08:52
Knowlesi ........ you often talk about High Risk etc as reviewed by your good self ... so can you pass comment on Genexine ?
2018, targeting patients with HPV (Human Papilloma Virus)-induced recurrent, relapsed, and metastatic cervical cancer.
The study is being conducted in seven major hospitals in Korea, including Seoul St. Mary’s Hospital, Asan Medical Center, and the National Cancer Center. Genexine and Merck & Co., Inc., Kenilworth, N.J., USA.adopted the Simon two-stage design, which mandates to see a response rate from at least 3 patients in Stage 1 out of maximum 15 patients enrolled. The response is defined as either complete or partial remission of cancer, indicated by the reduction of tumor size by a specific percentage. Genexine and Merck & Co., Inc., Kenilworth, N.J., USA.agreed to enter the Stage 2 earlier than planned after evaluating responses from 10 patients instead of 15, as the target response rate in Stage 1 was met including one of the patients showing complete response (CR). The study design allows enrolling total 28 patients for the Stage 2.